Literature DB >> 10731623

Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.

M E McCaul1, G S Wand, T Eissenberg, C A Rohde, L J Cheskin.   

Abstract

Preclinical studies support endogenous opioid system involvement in alcohol reinforcement and consumption; however, recent clinical trials and human laboratory studies have provided mixed findings of the effects of naltrexone (a non-selective opioid antagonist) on alcohol responses. This study used a within-subject design (n = 23) to investigate naltrexone effects (0, 50 and 100 mg qd) on subjective and psychomotor responses to alcohol (none, moderate, high) in heavy drinkers. Before alcohol administration, subjects reported decreased desire to drink alcohol when maintained on 50 mg compared with placebo naltrexone. Following alcohol administration, active naltrexone significantly increased subjective ratings of sedative, and unpleasant/sick effects and decreased ratings of liking, best effects and desire to drink. Naltrexone generally did not alter subjective or objective indicators of drunkenness. Finally, high doses of naltrexone and alcohol interacted to produce the greatest decreases in liking and best effects. Findings support the role of endogenous opioids as determinants of alcohol's effects and suggest that naltrexone may be particularly clinically useful in those treatment patients who continue to drink heavily.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731623     DOI: 10.1016/S0893-133X(99)00147-5

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  41 in total

1.  Anticraving agents for the treatment of addictive disorders.

Authors:  Charles P O'Brien
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 3.  Extended-release intramuscular naltrexone.

Authors:  Tracy Swainston Harrison; Greg L Plosker; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

Authors:  Stephanie S O'Malley; Suchitra Krishnan-Sarin; Sherry A McKee; Robert F Leeman; Ned L Cooney; Boris Meandzija; Ran Wu; Robert W Makuch
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-17       Impact factor: 5.176

5.  Naltrexone and combined behavioral intervention effects on trajectories of drinking in the COMBINE study.

Authors:  Ralitza Gueorguieva; Ran Wu; Dennis Donovan; Bruce J Rounsaville; David Couper; John H Krystal; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2009-12-06       Impact factor: 4.492

6.  Mechanisms of symptom reduction in a combined treatment for comorbid posttraumatic stress disorder and alcohol dependence.

Authors:  Carmen P McLean; Yi-Jen Su; Edna B Foa
Journal:  J Consult Clin Psychol       Date:  2015-06

7.  Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.

Authors:  Elise M Weerts; Gary S Wand; Hiroto Kuwabara; Cynthia A Munro; Robert F Dannals; John Hilton; J James Frost; Mary E McCaul
Journal:  Alcohol Clin Exp Res       Date:  2011-06-20       Impact factor: 3.455

Review 8.  Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes.

Authors:  Robert F Leeman; Markus Heilig; Christopher L Cunningham; David N Stephens; Theodora Duka; Stephanie S O'Malley
Journal:  Addict Biol       Date:  2010-04       Impact factor: 4.280

9.  Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Authors:  Robert Miranda; Stephanie S O'Malley; Hayley Treloar Padovano; Ran Wu; Daniel E Falk; Megan L Ryan; Joanne B Fertig; Thomas H Chun; Srinivas B Muvvala; Raye Z Litten
Journal:  Alcohol Clin Exp Res       Date:  2020-05-25       Impact factor: 3.455

Review 10.  Developing human laboratory models of smoking lapse behavior for medication screening.

Authors:  Sherry A McKee
Journal:  Addict Biol       Date:  2008-10-09       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.